{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:57:03Z","timestamp":1757703423239,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["KLI 694-B30"],"award-info":[{"award-number":["KLI 694-B30"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Austrian Research Promotion Agency","award":["FEMtec"],"award-info":[{"award-number":["FEMtec"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess in healthy volunteers the whole-body distribution and dosimetry of [<jats:sup>11<\/jats:sup>C]metoclopramide, a new positron emission tomography (PET) tracer to measure P-glycoprotein activity at the blood-brain barrier.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Procedures<\/jats:title>\n                <jats:p>Ten healthy volunteers (five women, five men) were intravenously injected with 387\u2009\u00b1\u200949\u00a0MBq of [<jats:sup>11<\/jats:sup>C]metoclopramide after low dose CT scans and were then imaged by whole-body PET scans from head to upper thigh over approximately 70\u00a0min. Ten source organs (brain, thyroid gland, right lung, myocardium, liver, gall bladder, left kidney, red bone marrow, muscle and the contents of the urinary bladder) were manually delineated on whole-body images. Absorbed doses were calculated with QDOSE (ABX-CRO) using the integrated IDAC-Dose 2.1 module.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The majority of the administered dose of [<jats:sup>11<\/jats:sup>C]metoclopramide was taken up into the liver followed by urinary excretion and, to a smaller extent, biliary excretion of radioactivity. The mean effective dose of [<jats:sup>11<\/jats:sup>C]metoclopramide was 1.69\u2009\u00b1\u20090.26\u00a0\u03bcSv\/MBq for female subjects and 1.55\u2009\u00b1\u20090.07\u00a0\u03bcSv\/MBq for male subjects. The two organs receiving the highest radiation doses were the urinary bladder (10.81\u2009\u00b1\u20090.23 \u03bcGy\/MBq and 8.78\u2009\u00b1\u20090.89 \u03bcGy\/MBq) and the liver (6.80\u2009\u00b1\u20090.78 \u03bcGy\/MBq and 4.91\u2009\u00b1\u20090.74 \u03bcGy\/MBq) for female and male subjects, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>[<jats:sup>11<\/jats:sup>C]Metoclopramide showed predominantly renal excretion, and is safe and well tolerated in healthy adults. The effective dose of [<jats:sup>11<\/jats:sup>C]metoclopramide was comparable to other <jats:sup>11<\/jats:sup>C-labeled PET tracers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11307-021-01582-4","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T15:27:47Z","timestamp":1611329267000},"page":"180-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4818-1560","authenticated-orcid":false,"given":"Martin","family":"Bauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Barna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Blaickner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Prosenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Bamminger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Karanikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, Huang SM, Tweedie DJ et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215\u2013236","journal-title":"Nat Rev Drug Discov"},{"key":"1582_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.clpt.2005.01.022","volume":"77","author":"L Sasongko","year":"2005","unstructured":"Sasongko L, Link JM, Muzi M et al (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503\u2013514","journal-title":"Clin Pharmacol Ther"},{"key":"1582_CR3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2967\/jnumed.113.130161","volume":"55","author":"AK Deo","year":"2014","unstructured":"Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, Richards TL, Mankoff DA, Minoshima S, O'Sullivan F, Eyal S, Hsiao P, Maravilla K, Unadkat JD (2014) Activity of P-glycoprotein, a beta-amyloid transporter at the blood-brain barrier, is compromised in patients with mild Alzheimer disease. J Nucl Med 55:1106\u20131111","journal-title":"J Nucl Med"},{"key":"1582_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/brain\/awr298","volume":"135","author":"DM van Assema","year":"2012","unstructured":"van Assema DM, Lubberink M, Bauer M et al (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135:181\u2013189","journal-title":"Brain"},{"key":"1582_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S1474-4422(13)70109-1","volume":"12","author":"M Feldmann","year":"2013","unstructured":"Feldmann M, Asselin M-C, Liu J, Wang S, McMahon A, Anton-Rodriguez J, Walker M, Symms M, Brown G, Hinz R, Matthews J, Bauer M, Langer O, Thom M, Jones T, Vollmar C, Duncan JS, Sisodiya SM, Koepp MJ (2013) P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol 12:777\u2013785","journal-title":"Lancet Neurol"},{"key":"1582_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2967\/jnumed.109.070151","volume":"51","author":"WC Kreisl","year":"2010","unstructured":"Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, Innis RB (2010) P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med 51:559\u2013566","journal-title":"J Nucl Med"},{"key":"1582_CR7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/cpt.1402","volume":"105","author":"M Bauer","year":"2019","unstructured":"Bauer M, Tournier N, Langer O (2019) Imaging P-glycoprotein function at the blood-brain barrier as a determinant of the variability in response to central nervous system drugs. Clin Pharmacol Ther 105:1061\u20131064","journal-title":"Clin Pharmacol Ther"},{"key":"1582_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2967\/jnumed.118.219972","volume":"60","author":"N Tournier","year":"2019","unstructured":"Tournier N, Bauer M, Pichler V, Nics L, Klebermass EM, Bamminger K, Matzneller P, Weber M, Karch R, Caill\u00e9 F, Auvity S, Marie S, J\u00e4ger W, Wadsak W, Hacker M, Zeitlinger M, Langer O (2019) Impact of P-glycoprotein function on the brain kinetics of the weak substrate 11C-metoclopramide assessed with PET imaging in humans. J Nucl Med 60:985\u2013991","journal-title":"J Nucl Med"},{"key":"1582_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2967\/jnumed.115.164350","volume":"57","author":"G Pottier","year":"2016","unstructured":"Pottier G, Marie S, Goutal S, Auvity S, Peyronneau MA, Stute S, Boisgard R, Dolle F, Buvat I, Caille F, Tournier N (2016) Imaging the impact of the P-glycoprotein (ABCB1) function on the brain kinetics of metoclopramide. J Nucl Med 57:309\u2013314","journal-title":"J Nucl Med"},{"key":"1582_CR10","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2967\/jnumed.118.210104","volume":"59","author":"S Auvity","year":"2018","unstructured":"Auvity S, Caill\u00e9 F, Marie S, Wimberley C, Bauer M, Langer O, Buvat I, Goutal S, Tournier N (2018) P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood-brain barrier: a PET study on non-human primates. J Nucl Med 59:1609\u20131615","journal-title":"J Nucl Med"},{"key":"1582_CR11","doi-asserted-by":"publisher","unstructured":"Bauer M, Bamminger K, Pichler V et al (2020) Impaired clearance from the brain increases the brain exposure to metoclopramide in elderly subjects. Clin Pharmacol Ther 2020 Sep 23. https:\/\/doi.org\/10.1002\/cpt.2052. Online ahead of print","DOI":"10.1002\/cpt.2052"},{"key":"1582_CR12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2967\/jnumed.119.237198","volume":"61","author":"V Zoufal","year":"2020","unstructured":"Zoufal V, Mairinger S, Brackhan M, Krohn M, Filip T, Sauberer M, Stanek J, Wanek T, Tournier N, Bauer M, Pahnke J, Langer O (2020) Imaging P-glycoprotein induction at the blood-brain barrier of a beta-amyloidosis mouse model with 11C-metoclopramide PET. J Nucl Med 61:1050\u20131057","journal-title":"J Nucl Med"},{"key":"1582_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41181-019-0083-2","volume":"4","author":"V Pichler","year":"2019","unstructured":"Pichler V, Ozenil M, Bamminger K, Vraka C, Hacker M, Langer O, Wadsak W (2019) Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramide. EJNMMI Radiopharm Chem 4:31","journal-title":"EJNMMI Radiopharm Chem"},{"key":"1582_CR14","first-page":"378","volume":"31","author":"HL Atkins","year":"1990","unstructured":"Atkins HL, Thomas SR, Buddemeyer U, Chervu LR (1990) MIRD dose estimate report no. 14: radiation absorbed dose from technetium-99m-labeled red blood cells. J Nucl Med 31:378\u2013380","journal-title":"J Nucl Med"},{"key":"1582_CR15","doi-asserted-by":"crossref","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S (2017) IDAC-dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI res 7:88","DOI":"10.1186\/s13550-017-0339-3"},{"key":"1582_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2125.1980.tb01064.x","volume":"9","author":"DN Bateman","year":"1980","unstructured":"Bateman DN, Kahn C, Davies DS (1980) The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol 9:371\u2013377","journal-title":"Br J Clin Pharmacol"},{"key":"1582_CR17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1124\/dmd.110.033357","volume":"38","author":"UA Argikar","year":"2010","unstructured":"Argikar UA, Gomez J, Ung D, Parkman HP, Nagar S (2010) Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies. Drug Metab Dispos 38:1295\u20131307","journal-title":"Drug Metab Dispos"},{"key":"1582_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/BF00315511","volume":"45","author":"A Hellstern","year":"1993","unstructured":"Hellstern A, Hellenbrecht D, Saller R, Gatzen M, Achtert G, Brockmann P, Hausleiter HJ (1993) Minimal biliary excretion and enterohepatic recirculation of metoclopramide in patients with extrahepatic cholestasis. Eur J Clin Pharmacol 45:415\u2013418","journal-title":"Eur J Clin Pharmacol"},{"key":"1582_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.nucmedbio.2011.08.005","volume":"39","author":"J van der Aart","year":"2012","unstructured":"van der Aart J, Hallett WA, Rabiner EA, Passchier J, Comley RA (2012) Radiation dose estimates for carbon-11-labelled PET tracers. Nucl Med Biol 39:305\u2013314","journal-title":"Nucl Med Biol"},{"key":"1582_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pharmthera.2018.04.006","volume":"189","author":"N Tournier","year":"2018","unstructured":"Tournier N, Stieger B, Langer O (2018) Imaging techniques to study drug transporter function in vivo. Pharmacol Ther 189:104\u2013122","journal-title":"Pharmacol Ther"},{"key":"1582_CR21","first-page":"1","volume":"37","author":"The","year":"2007","unstructured":"The (2007) Recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP 37:1\u2013332","journal-title":"Ann ICRP"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01582-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-021-01582-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01582-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T21:10:07Z","timestamp":1614373807000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-021-01582-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s11307-021-01582-4","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"type":"print","value":"1536-1632"},{"type":"electronic","value":"1860-2002"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"24 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the most recent version of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest. AIT Austrian Institute of Technology has out-licensed a segmentation algorithm to ABX-CRO to be used in QDOSE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}